Interventions for preventing neuropathy caused by cisplatin and related compounds

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Albers, James W ^a   Chaudhry, Vinay ^b   Cavaletti, Guido ^c   Donehower, Ross C ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; CALCIUM; CISPLATIN; CORTICOTROPIN; DIETHYLDITHIOCARBAMIC ACID; DIMESNA; GLUTATHIONE; LEVACECARNINE; MAGNESIUM; OXCARBAZEPINE; PLACEBO; RETINOIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ANEMIA; BLOOD TOXICITY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOTENSION; LENGTH OF STAY; LEUKOPENIA; NAUSEA AND VOMITING; NERVE CONDUCTION; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; OUTCOME ASSESSMENT; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VIBRATION SENSE; VOMITING; CHEMICALLY INDUCED DISORDER; META ANALYSIS; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907424832     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005228.pub4     Document Type: Review

References (106)

1. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, et al.A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006;14(11):1134-40. [PUBMED: 16622646]
2. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al.Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67(12):2253-5. [PUBMED: 17190958]
3. Arrieta Ó, Hernández-Pedro N, Fernández-González-Aragón MC, Saavedra-Pérez D, Campos-Parra AD, Ríos-Trejo MÁ, et al.Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 2011;77(10):987-95. [PUBMED: 21865574]
4. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantu MG, Cavaletti G. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. International Journal of Gynecological Cancer 1996;6(5):415-9.
5. Cascinu S, Cordella L, Del FE, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13(1):26-32. [PUBMED: 7799029]
6. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al.Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002;20(16):3478-83. [PUBMED: 12177109]
7. Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, et al.Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pacific Journal of Clinical Oncology 2010;6(4):270-7. [PUBMED: 21114776]
8. Colombo N, Bini S, Miceli D, Bogliun G, Marzorati L, Cavaletti G, et al.Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. International Journal of Gynecological Cancer 1995;5(2):81-6. [PUBMED: 11578459]
9. de Vos FY, Bos AM, Schaapveld M, Swart CA, Graaf H, et al.A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecologic Oncology 2005;97(1):60-7. [PUBMED: 15790438]
10. Gallardo D, Mohar A, Calderillo G, Mota A, Solorza G, Lozano A, et al.Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix. International Journal of Gynecological Cancer 1999;9(3):225-30. [PUBMED: 11240771]
11. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, et al.Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. Journal of Clinical Oncology 1995;13(2):490-6. [PUBMED: 7844610]
12. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al.Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. Journal of Clinical Oncology 2011;29(4):421-7. [PUBMED: 21189381]
13. Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. Journal of Neurology 1992;239(3):143-6. [PUBMED: 1315383]
14. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. International Journal of Clinical Oncology 2010;15(1):82-7. [PUBMED: 20108160]
15. Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, et al.Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Medical Oncology 2003;20(3):237-45. [PUBMED: 14514973]
16. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al.Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Journal of Clinical Oncology 1996;14(7):2101-12. [PUBMED: 8683243]
17. Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Seminars in Oncology 1996;23(4 Suppl 8):83-9. [PUBMED: 8783673]
18. Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, et al.The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. European Journal of Cancer 2011;47(3):369-74. [PUBMED: 21067912]
19. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al.The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Supportive Care in Cancer 2011;19(11):1769-77. [PUBMED: 20936417]
20. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, et al.N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Supportive Care in Cancer 2006;14(5):484-7. [PUBMED: 16450089]
21. Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, et al.Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93. [PUBMED: 12853351]
22. Lu P, Fan QX, Wang LX, Wang X, Zong H, Wang RL. Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors. Ai Zheng [Chinese Journal of Cancer] 2008;27(10):1117-20.
23. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 2009;20(5):396-402. [PUBMED: 19287306]
24. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del MG, et al.Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology 2003;21(5):927-31. [PUBMED: 12610195]
25. Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, et al.Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Annals of Oncology 1999;10(6):693-700. [PUBMED: 10442192]
26. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecologic Oncology 1997;67(2):172-7. [PUBMED: 9367703]
27. Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, et al.Glutathione in the prevention of cisplatin induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wiener Klinische Wochenschrift 2000;112(14):617-23. [PUBMED: 11008323]
28. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al.Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Annals of Oncology 1997;8(6):569-73. [PUBMED: 9261526]
29. Gerritsen van der Hoop R, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, et al.Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. New England Journal of Medicine 1990;322(2):89-94. [PUBMED: 2152972]
30. van Gerven JMA, Hovestadt A, Moll JW, Rodenburg CJ, Splinter TA, van Oosterom AT, et al.The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. Journal of Neurology 1994;241(7):432-5. [PUBMED: 7931444]
31. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic & Clinical Pharmacology & Toxicology 2009;106:272-9.
32. Ao R, Wang Y-H, Li R-W, Wang Z-R. Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: a meta-analysis. Experimental and Therapeutic Medicine 2012;4(5):933-7.
33. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al.Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64(1):26-31.
34. Block KI, Gyllenhaal C. Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care. Integrative Cancer Therapies 2005;4(4):329-51.
35. Bogliun G, Marzorati L, Cavaletti G, Frattola L. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Italian Journal of Neurological Sciences 1992;13(8):643-7.
36. Program in Evidence-based Care. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Toronto (ON): Cancer Care Ontario; 2012 May 15 [Archived 2011 Sep]. Program in Evidence-based Care Evidence-based Series No.: 12-6 ARCHIVED 2011. https://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/systemic-ebs/ (accessed 12 September 2013).
37. Capizzi RL, Oster W, Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. European Journal of Cancer 1995;31A(Suppl 1):S8-13.
38. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, et al.Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemotherapy & Pharmacology 1998;41(2):161-6.
39. Catalano V. An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients [abstract no: 1529]. European Journal of Cancer 1999;35:S375.
40. Chen XF, Wang R, Yin YM, Roe OD, Li J, Zhu LJ, et al.The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. Biomedicine & Pharmacotherapy 2012;66(4):279-84.
41. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61(5):641-84.
42. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007;21(Suppl 1):39-43.
43. De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, et al.A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecologic Oncology 2005;97(1):60-7.
44. Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 2003;14(6):423-5.
45. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, et al.Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 2004;10(12 Pt 1):4055-61.
46. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, et al.Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy (letter). Journal of Clinical Oncology 2008;26(7):1188-9.
47. Gedlicka C, Kornek GV, Schmid K, Scheithauer W. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid (letter). Annals of Oncology 2003;14(2):339-40.
48. Gispen WH, Hamers FP, Vecht CJ, Jennekens FG, Neyt JP. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. Journal of Steroid Biochemistry & Molecular Biology 1992;43(1-3):179-83.
49. Glover D, Glick JH, Weiler C. WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. Journal of Clinical Oncology 1987;5(4):574-8.
50. Glover D, Grabelsky S, Fox K, Weiler C, Cannon L, Glick J. Clinical trials of WR-2721 and cis-platinum. International Journal of Radiation Oncology, Biology, Physics 1989;16(5):1201-4.
51. Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, et al.Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1686). Melanoma Research 2003;13(6):619-26.
52. Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, et al.A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer 2001;92(10):2517-22.
53. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clinical Colorectal Cancer 2005;5(Suppl 1):S38-S46.
54. Haigentz JM, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, et al.Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anti-Cancer Drugs 2003;14(4):321-6.
55. Heidenreich A, Marx FJ, Peters HJ, Engelmann UH, Hannappel J, Leusmann D. Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer. [German]. Urologe 1999;38(6):586-91.
56. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al.American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology 2009;27(1):127-45.
57. Hilkens PH, van-der-Burg ME, Moll JW, Planting AS, van-Putten WL, Vecht CJ, et al.Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. European Journal of Cancer 1995;31A(5):678-81.
58. Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, et al.Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Supportive Care in Cancer 2005;13(10):797-805.
59. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. Journal of Clinical Oncology 2007;25(25):4028-9.
60. Kesari S, Wen PY. Neuroprotective effect of vitamin E supplementation (commentary). Neurology 2005;64(1):1.
61. Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, et al.Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Journal of Clinical Oncology 2003;21(9):1767-74.
62. Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, et al.Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Supportive Care in Cancer 1997;5(2):126-9.
63. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, et al.Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. European Journal of Cancer 1999;35(12):1688-92.
64. Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, et al.A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo 2002;16(2):93-6.
65. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, et al.Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). Journal of Thoracic Oncology 2008;3(10):1159-65.
66. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61(11):2192-5.
67. Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al.Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21(22):4207-13. [PUBMED: 14615449]
68. Pace A, Bove L, Jandolo B. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;65(3):501-2.
69. Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, Della GM, et al.Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010;74(9):762-6.
70. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Annals of Oncology 2001;12(3):421-2.
71. Rick O, Beyer J, Schwella N, Schubart H, Schleicher J, Siegert W. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Annals of Oncology 2001;12(8):1151-5.
72. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al.Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12(3):312-9.
73. Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, et al.Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Annals of Oncology 2013;24(1):171-8. [PUBMED: 22898039]
74. Wilkes G. Peripheral neuropathy related to chemotherapy. Seminars in Oncology Nursing 2007;23(3):162-73.
75. Dong M, Xing PY, Liu P, Feng FY, Shi YK. [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 2010;32(3):208-11. [PUBMED: 20450590]
76. Pang DM, Deng YM, Lan XS, Feng WN, Liang JM, Xu YH. Efficacy of reduced glutathione in preventing and reducing neurotoxicity of oxaliplatin [Chinese]. Chinese Journal of Cancer Prevention and Treatment 2010;17:2059.
77. Romano LM. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. [Spanish]. Neurologia Argentina 2011;3:146.
78. Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, et al.Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Experimental Neurology 2010; Vol. 226, issue 2:301-9.
79. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathologica 1992;84(4):364-71.
80. Cavaletti G, Marmiroli P, Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Drug Safety 2004;3(6):535-46.
81. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al.Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. European Journal of Cancer 2010;46(3):479-94.
82. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology 2013;24(2):454-62.
83. Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FG. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. Journal of the Neurological Sciences 1989;93(2-3):167-74.
84. Gandara DR, Perez EA, Weibe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Seminars in Oncology 1991;18(1 Suppl 3):49-55.
85. Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Seminars in Oncology 2003;30(4 Suppl 15):5-13.
86. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy 2004;5(10):2159-70.
87. Higgins JPT, Green SE (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
88. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
89. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, et al.Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 1993;116(Pt 5):1017-41.
90. Links M, Lewis C, Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57(3):293-308.
91. Mollman JE. Cisplatin neurotoxicity. New England Journal of Medicine 1990;322(2):126-7.
92. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, et al.Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle & Nerve 2001;24:1050-7.
93. Pisano C, Pratesi G, Laccabue D, Zunino F, Giudice PL, Bellucci A, et al.Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clinical Cancer Research 2003;9(15):5756-67.
94. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treatment Reviews 1979;6:17-39.
95. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology (Minneap) 1984;34:934-8.
96. Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Seminars in Oncology 1996;23(4 Suppl 8):83-9.
97. Schmidt Y, Unger JW, Bartke I, Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Experimental Neurology 1995;132(1):16-23.
98. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54(7):1269-75.
99. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathologica 1986;69(3-4):295-308.
100. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al.Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treatment Report 1979;63(9-10):1527-31.
101. Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B. Cisplatin neuropathy: clinical and nerve conduction correlation (abstr). Muscle & Nerve 1994;17:1116-7.
102. Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B. Cisplatin neuropathy not prevented by ACTH(4-9) analog (abstr). Neurology 1995;45 (Suppl 4):A170.
103. Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994;44(3 Pt 1):488-94.
104. Albers J, Chaudhry V, Donehower R, Cavaletti G. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005228]
105. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005228.pub2]
106. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD005228.pub3]